## **Supporting Information**

# Peptide Nanofiber Complexes with siRNA for Deep Brain Gene Silencing by Stereotactic Neurosurgery

Mariarosa Mazza, Marilena Hadjidemetriou, Irene de Lazaro, Cyrill Bussy, Kostas Kostarelos\*

Nanomedicine Lab, Institute of Inflammation and Repair, Faculty of Medical & Human Sciences, AV Hill Building, The University of Manchester, Manchester M13 9PT, United Kingdom

\* Correspondence to: <a href="mailto:kostarelos@manchester.ac.uk">kostas.kostarelos@manchester.ac.uk</a>









**Supporting Figure 1: Cellular internalization of PNF:siRNA. (A)** Confocal laser scanning microscopy pictures of primary rat neurons treated with fluorescently labelled PNFs (BF = bright field; Scale bar = 20 microns). **(B)** PNFs were covalently tagged with Vivo-Tag 680 XL (red) and siRNA was labelled with Alexa 546 (green). Cell nuclei were stained with DAPI (blue). 20X magnification; Scale bar = 10 microns) . **(C)** unmerged channels of SH-SY5Y cell incubated with fluorescently-labelled PNF:siRNA complexes.

### **Supporting Figure 1**



**Supporting Figure 2: Cytotoxicity of PNFs as function of concentration on SH-SY5Y cells. (A)** LDH release normalised to 1% Triton –treated cells, exposed to increasing concentration ( $\mu$ g/mL) of PNFs after 4h incubation in serum-free media (black column) and 4 hr incubation in serum-free media followed 20h recovery in FBS (grey column). (B) LDH release normalised to 1% Triton –treated cells exposed to increasing concentration ( $\mu$ g/mL) of PNFs in serum supplemented (FBS) media after 4h (black column) and 24h (grey column) (Two-way ANOVA, P<0.0001).

#### **Supporting Figure 2**

A								
BF	DAPI	СуЗ	Overlay	BF	DAPI	СуЗ	Overlay	
	the to			Å	S		Å	control
e er	" 4" 5		**	B	а <sup>н</sup> То		8°	siNEG
	and a			ST .	8			PNF:siNEG
	132				$\gamma(x)$			siBcl-2
				18 EST E	" 4". "			PNF:siBcl-2
·				L	,			

4h

24h



**Supporting Figure 3: Immunofluorescence assessment of Bcl-2 knockdown. (A)** Epi-fluorescence images of human SH-SY5Y 4h and 24h after transfection. The specificity of the Bcl-2 antibody was assessed by treating the transfected cells with the secondary antibody only tagged with Cy3. There was no detactable fluorescence in the Cy3 channel, confirming the Bcl-2 antibody specificity. **(B)** Immunofluorescence with caspase-3 specific antibody 4h post-transfection. Only cells treated with PNF/siBcl2 showed expression of caspase-3 (red fluorescence; BF=bright field). **(C)** Bcl2 levels after gene silencing in SH-SY5Y cells with siNEG and PNF:siNEG control treatment groups.

### **Supporting Figure 3**



**Supporting Figure 4: (A)** Epi-fluorescence microscopy images of TUNEL staining on transfected SH-SY5Ycells for the detection of apoptosis. 4 hours after transfection more cells undergo apoptosis with the PNF:siBcl-2 treatment in comparison to the conventional transfection agent Lipofectamine (Lipofectamine:siBcl-2). Magnification 20X; Scale bar is 40 microns; BF= bright field). **(B)** Epi-fluorescence microscopy images of TUNEL staining on transfected SH-SY5Ycells with siNEG and PNF:siNEG control treatment groups. Of note there is some background green fluorescence.

#### **Supporting Figure 4**

В